Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q0VDG4
UPID:
SCRN3_HUMAN
Alternative names:
-
Alternative UPACC:
Q0VDG4; B4DI11; C9JPC1; D3DPE0; Q7L1C5; Q9H5R5
Background:
Secernin-3, encoded by the gene symbolized as Q0VDG4, plays a pivotal role in cellular processes, although its specific functions are yet to be fully elucidated. This protein's involvement in intracellular signaling pathways highlights its importance in maintaining cellular homeostasis and regulating cell function.
Therapeutic significance:
Understanding the role of Secernin-3 could open doors to potential therapeutic strategies. Its involvement in critical cellular processes suggests that targeting Secernin-3 could lead to innovative treatments for diseases where these processes are disrupted.